ART BioScience
Genetic Therapies for Duchenne Muscular Dystrophy
Health Tech & Life Sciences
Private
Company Overview
Snapshot
Founded in July 2015 by Oren Ozeri and Alon Hazan, ART BioScience operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing novel messenger RNA technologies.
Business overview
ART BioScience specializes in developing therapeutics for Duchenne Muscular Dystrophy, leveraging novel messenger RNA technologies. The company's core technology involves proprietary LNP-based formulations optimized for effective muscle delivery of mRNA via systemic administration. ART BioScience serves the pharmaceutical and life sciences industries, operating within the Health Tech & Life Sciences sector, specifically focusing on drug discovery and development for rare diseases.
Company Intelligence Q&A
- What is ART BioScience's primary focus?
- ART BioScience is focused on developing genetic therapies for Duchenne Muscular Dystrophy using novel messenger RNA technologies.
- When was ART BioScience founded?
- ART BioScience was founded in July 2015.
- Who are the founders of ART BioScience?
- ART BioScience was founded by Oren Ozeri and Alon Hazan.
- What is ART BioScience's core technology?
- ART BioScience utilizes proprietary LNP-based formulations to enable efficient systemic delivery of mRNA to muscles for therapeutic purposes.
- What is the current product stage of ART BioScience?
- ART BioScience is currently in the R&D product stage, as of January 2023, focusing on developing novel messenger RNA technologies.